AEMD recently made some headcount reductions and other cost reductions and stands to benefit from the up to 43.5% cash tax rebate on clinical trial-related R&D costs in Australia. Moreover, conducting studies in both Australia and India will lower overall clinical spending and also enable the company to determine the Hemopurifier's impact on diverse patient populations. The primary endpoint of the trial is safety and it will also assess feasibility and optimal treatment levels. AEMD is optimistic that the trial will show the Hemopurifier's ability in conjunction anti-PD1 agents to improve the body's ability to fight cancer. Longer-term, AEMD continues to view the Hemopurifier as a potential tool in the treatment of viruses, organ transplants and other medical areas.
